T3/T4 Thyroid Blend

• •If you genuinely have hypothyroidism and are correctly dosed: gradual resolution of fatigue, cold intolerance, weight gain, dry skin and brain fog over weeks - not an overnight or 'enhanced' effect.

• •T3's fast action can produce noticeable short-term stimulation (warmth, faster heart rate) after a dose; that is a warning sign of overshoot as often as a 'benefit.'

• •Feeling wired, hot, shaky, or having a racing/irregular heartbeat means you are likely over-dosed (thyrotoxic) - a reason to get labs, not to push higher.

• •Any benefit over T4-alone is subtle and not guaranteed; many people notice no difference in blinded trials [PMID:30550536].

• •This is a maintenance therapy for a real deficiency, not a cycle-able enhancement drug.

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Additional Dosage Notes

The individual hormones are among the most-studied and most-prescribed drugs in medicine: levothyroxine (T4) is the established standard of care for hypothyroidism, and liothyronine (T3) is an approved thyroid hormone [PMID:35589725]. The fixed T3/T4 'blend' sold as a research chemical, however, has NO clinical trials of its own. What has been studied is levothyroxine + liothyronine COMBINATION therapy versus levothyroxine alone. Across roughly 14 randomized controlled trials and multiple meta-analyses, combination therapy has not shown a consistent, reproducible benefit over levothyroxine monotherapy for quality of life, mood, cognition, fatigue or body weight [PMID:33276704] [PMID:30550536]. The 2014 American Thyroid Association treatment guideline concluded levothyroxine should remain the standard of care and found no strong evidence that combination or extract therapy is superior [PMID:25266247]; the 2015 British Thyroid Association statement reached the same conclusion [PMID:26010808]. A 2021 ATA/BTA/ETA consensus judged there is 'equipoise' - enough residual uncertainty to justify better-designed future trials targeting suspected under-converters and using slow-release T3 - but did not endorse routine combination use [PMID:33276704]. Bottom line: this is a legitimate area of ongoing research, but the blend is not a proven upgrade, and self-directed use outside a monitored, diagnosed deficiency is not supported by evidence.

Nearly all serious effects come from too much thyroid hormone (over-replacement / thyrotoxicosis), and the T3 component makes overshoot easier because it acts fast and potently. Cardiac: palpitations, tachycardia, new or worsened atrial fibrillation, angina, and increased cardiac workload; a suppressed TSH is independently linked to higher atrial fibrillation risk [PMID:33543160] [PMID:23873176]. Skeletal: accelerated bone turnover and loss of bone mineral density with increased fracture risk - especially hip and spine - when TSH is suppressed, shown in a pooled analysis of roughly 70,000 participants [PMID:26010634] [PMID:22561612]. Metabolic/general: heat intolerance, sweating, unwanted weight loss, tremor, anxiety, insomnia, diarrhea, menstrual changes and muscle weakness. Risks are higher in older adults and anyone with heart disease. Post-dose T3 peaks from the liothyronine component can cause transient palpitations even at an 'average' daily total. Under-dosing simply leaves hypothyroid symptoms uncorrected.